High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR

This study was designed to determine whether advanced non-small-cell lung cancer (NSCLC) patients with high copy number of epidermal growth factor receptor (EGFR) can benefit from treatment with EGFR-tyrosine kinase inhibitors (TKIs). EGFR gene copy number was assessed by fluorescence in situ hybrid...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of translational medicine 2013-04, Vol.11 (1), p.90-90, Article 90
Hauptverfasser:	Wang, Fang, Fu, Sha, Shao, Qiong, Zhou, Yan-Bin, Zhang, Xiao, Zhang, Xu, Xue, Cong, Lin, Jian-Guang, Huang, Li-Xia, Zhang, Li, Zhang, Wei-Min, Shao, Jian-Yong
Format:	Artikel
Sprache:	eng
Schlagworte:	Brain research Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Care and treatment Chemotherapy Clinical medicine Development and progression Disease-Free Survival ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Family medical history Gene Dosage Hospitals Humans In Situ Hybridization, Fluorescence Kaplan-Meier Estimate Lung cancer, Non-small cell Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Medical imaging Mutation Mutation - genetics NMR Nuclear magnetic resonance Oncology Patient outcomes Patients Physiological aspects Proportional Hazards Models Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Survival Analysis Treatment Outcome Tumors Tyrosine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!